Chembio Diagnostics Strengthens Commercial Organization
June 02 2020 - 8:00AM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostic company focused on infectious diseases,
today announced that Chuck Caso has been appointed Vice President
of Sales and Marketing for North America, effective immediately. In
this new role, Mr. Caso will be responsible for all direct and
channel sales efforts throughout the region.
“We are very excited to have Chuck join Chembio to
bolster our commercial efforts in North America, and particularly
the United States, at this critical and pivotal point for the
company. His accomplishments and experience in the industry give us
great confidence he is the ideal candidate to lead our North
American sales team as we refocus the company on the COVID
opportunity domestically and continue to establish DPP as a leading
point-of-care diagnostics platform,” said Richard Eberly, President
and Chief Executive Officer of Chembio. “Chuck has demonstrated
great vision, leadership and results during his career. He has deep
knowledge of our market, products, customers and channel partners,
and a proven ability to transform that knowledge into actionable
results and profitable sales growth.”
“I am very pleased to be joining Chembio and taking
on this new challenge to lead the sales and marketing efforts in
North America. The company is well positioned to serve the many
customer channels that can all benefit from the accuracy, speed and
ease of use provided by DPP technology,” said Mr. Caso. “I look
forward to working with this talented team to implement and execute
commercial strategies to deliver our DPP COVID-19 program and
legacy business product portfolios to a diverse customer base.”
Mr. Caso brings more than 20 years of diagnostic
industry experience to his new role. Previously, he served in
various Executive Sales and Marketing roles at leading companies
such as Meridian Biosciences, Quest and Danaher. Mr. Caso received
a Master of Business Administration degree from the University of
Pittsburgh and a Bachelor of Science degree from the Indiana
University of Pennsylvania.
About Chembio DiagnosticsChembio
is a leading point-of-care diagnostics company focused on detecting
and diagnosing infectious diseases, including COVID-19, sexually
transmitted disease, and fever and tropical disease. The company’s
patented DPP technology platform, which uses a small drop of blood
from the fingertip, provides high-quality, cost-effective results
in approximately 15 minutes. Coupled with Chembio’s extensive
scientific expertise, its novel DPP technology offers broad market
applications beyond infectious disease. Chembio’s products are sold
globally, directly and through distributors, to hospitals and
clinics, physician offices, clinical laboratories, public health
organizations, government agencies, and consumers. Learn more at
www.chembio.com.
DPP is Chembio’s registered trademark. For
convenience, this trademark appears in this release without ®
symbols, but that practice does not mean that Chembio will not
assert, to the fullest extent under applicable law, its rights to
the trademark.
Contact:Philip TaylorGilmartin
Group(415) 937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024